The company maintains a precarious financial position characterized by a persistent negative equity balance of -$37.3 million and a total asset base that has eroded to $20.0 million as of 2026Q1.
Atara Biotherapeutics, Inc. (ATRA) balance sheet — 14-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 13.53M | 12.21M | 64.89M | 101.87M | 295.08M | 384.62M | 523.27M | 272.99M | 321.49M | 172.19M | 260.55M | 324.6M | 106.03M | 51.81M | 4.24M |
| Cash & Short-Term Investments | 9.87M | 8.48M | 42.5M | 51.73M | 242.82M | 371.07M | 500.66M | 259.11M | 309.63M | 166.1M | 255.68M | 320.48M | 104.12M | 51.62M | 4.21M |
| Cash Only | 3.22M | 8.48M | 25.03M | 25.84M | 92.94M | 106.08M | 200.4M | 74.32M | 60.7M | 79.22M | 47.97M | 23.75M | 21.9M | 51.62M | 4.21M |
| Short-Term Investments | 6.65M | 0 | 17.47M | 25.88M | 149.88M | 264.98M | 300.25M | 184.79M | 248.93M | 86.87M | 207.71M | 296.74M | 82.22M | 0 | 0 |
| Accounts Receivable | 318K | 1.25M | 1.48M | 34.11M | 40.22M | 986K | 1.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 51.33 | 3.79 | 4.2 | 1.45K | 230.93 | 17.69 | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 10.65M | 9.71M | 1.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | 185.11 | 398.68 | 2.14 | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.34M | 2.48M | 10.26M | 6.33M | 10.45M | 194K | 194K | 194K | 194K | 194K | 194K | 194K | 0 | 0 | 35K |
| Total Non-Current Assets | 7.49M | 8.02M | 44.2M | 63.63M | 81.34M | 83.51M | 64.85M | 69.95M | 70.35M | 45.59M | 3.36M | 378K | 96K | 20K | 48K |
| Property, Plant & Equipment | 6.73M | 7.14M | 41.1M | 58.79M | 74.32M | 79.94M | 62.82M | 68.18M | 68.58M | 44.13M | 3.26M | 270K | 48K | 8K | 9K |
| Fixed Asset Turnover | 0.78x | 16.92x | 3.14x | 0.15x | 0.86x | 0.25x | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 765K | 886K | 3.1M | 4.84M | 7.02M | 3.57M | 2.03M | 1.77M | 574K | 1.46M | 102K | 108K | 48K | 12K | 39K |
| Total Assets | 21.02M | 20.23M | 109.1M | 165.5M | 376.42M | 468.13M | 588.12M | 342.94M | 391.84M | 217.78M | 263.91M | 324.98M | 106.12M | 51.83M | 4.29M |
| Asset Turnover | 0.27x | 5.97x | 1.18x | 0.05x | 0.17x | 0.04x | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -271.11% | -81.45% | -34.08% | -56.03% | -19.59% | -20.4% | 71.49% | -12.48% | 79.93% | -17.48% | -18.79% | 206.23% | 104.76% | 1108.11% | - |
| Total Current Liabilities | 6.85M | 14.92M | 134.57M | 142.23M | 78.92M | 105.79M | 82.9M | 36.74M | 39.98M | 27.65M | 9.68M | 9.71M | 2.72M | 1.52M | 1.3M |
| Accounts Payable | 824K | 127K | 4.37M | 3.68M | 6.87M | 17.37M | 7.12M | 7.96M | 3.72M | 14.71M | 2.78M | 1.45M | 440K | 606K | 0 |
| Days Payables Outstanding | 325.7 | 2.19 | 75.87 | 151.32 | 9.29 | 22.48 | 10.62 | - | 359.01 | 5.62K | 2.65K | 10.99K | - | - | - |
| Short-Term Debt | 0 | 10.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1M |
| Deferred Revenue (Current) | 3.19M | 716K | 95.09M | 77.83M | 8M | 40.76M | 33.45M | 0 | -490K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.4M | 2.03M | 6.59M | 37.01M | 32.75M | 25.15M | 19.89M | 14.71M | 0 | 500K | 0 | 0 | 0 | 155K | 241K |
| Current Ratio | 1.98x | 0.82x | 0.48x | 0.72x | 3.74x | 3.64x | 6.31x | 7.43x | 8.04x | 6.23x | 26.93x | 33.43x | 38.92x | 33.99x | 3.26x |
| Quick Ratio | 1.98x | 0.82x | 0.40x | 0.65x | 3.72x | 3.64x | 6.31x | 7.43x | 8.04x | 6.23x | 26.93x | 33.43x | 38.92x | 33.99x | 3.26x |
| Cash Conversion Cycle | -274.37 | - | 113.44 | 1.7K | 223.78 | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 51.17M | 43.81M | 71.81M | 122.51M | 170.86M | 82.73M | 42.88M | 15.42M | 13M | 12.27M | 503K | 166K | 216K | 61.32M | 4K |
| Long-Term Debt | 0 | 32.67M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 33.13M | 9.35M | 29.91M | 45.69M | 58.06M | 25.52M | 13.04M | 14.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 42.39M | 1.79M | 41.89M | 39.25M | 35.8M | 1.5M | 2.04M | 1.28M | 13M | 12.27M | 503K | 166K | 216K | 61.32M | 4K |
| Total Liabilities | 58.02M | 58.74M | 206.38M | 264.74M | 249.78M | 188.51M | 125.78M | 52.16M | 52.98M | 39.91M | 10.18M | 9.88M | 2.94M | 62.84M | 1.31M |
| Total Debt | 9.88M | 52.8M | 43.83M | 57.87M | 71.7M | 28.27M | 15.03M | 15.72M | 738K | 0 | 0 | 0 | 0 | 0 | 1M |
| Net Debt | 6.66M | 44.32M | 18.8M | 32.03M | -21.24M | -77.81M | -185.38M | -58.6M | -59.96M | -79.22M | -47.97M | -23.75M | -21.9M | -51.62M | -3.2M |
| Debt / Equity | -0.27x | - | - | - | 0.57x | 0.10x | 0.03x | 0.05x | 0.00x | - | - | - | - | - | 0.34x |
| Debt / EBITDA | -0.70x | 1.39x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.47x | 1.17x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -4.90x | 9.63x | -17.51x | -51.24x | -611.04x | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -37M | -38.5M | -97.28M | -99.23M | 126.64M | 279.61M | 462.34M | 290.78M | 338.86M | 177.86M | 253.74M | 315.1M | 103.18M | -11.02M | 2.98M |
| Equity Growth % | 146.63% | 60.42% | 1.96% | -178.36% | -54.71% | -39.52% | 59% | -14.19% | 90.51% | -29.9% | -19.47% | 205.38% | 1036.57% | -469.2% | - |
| Book Value per Share | -2.46 | -3.03 | -12.99 | -23.42 | 31.04 | 74.63 | 156.25 | 141.68 | 193.36 | 148.90 | 220.78 | 307.92 | 517.36 | -285.17 | 4.07 |
| Total Shareholders' Equity | -37M | -38.5M | -97.28M | -99.23M | 126.64M | 279.61M | 462.34M | 290.78M | 338.86M | 177.86M | 253.74M | 315.1M | 103.18M | -11.02M | 2.98M |
| Common Stock | 1K | 1K | 1K | 11K | 10K | 9K | 8K | 6K | 5K | 3K | 3K | 3K | 2K | 1K | 1K |
| Retained Earnings | -2.03B | -2.02B | -2.05B | -1.97B | -1.69B | -1.46B | -1.12B | -817.96M | -527.35M | -296.65M | -177.16M | -98.11M | -40.89M | -12.88M | -4.11M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.2M | 0 |
| Accumulated OCI | -2K | 1K | 8K | -204K | -2.07M | -368K | 296K | 220K | -340K | -151K | -183K | -518K | -100K | -335K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ATRA stock.
As of 2025, Atara Biotherapeutics, Inc. (ATRA) had total assets of $20.2M including $12.2M in current assets.
Atara Biotherapeutics, Inc. (ATRA) carries total debt of $52.8M, offset by $8.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Atara Biotherapeutics, Inc. (ATRA) has total shareholders' equity (book value) of $-38.5M ($-3.03 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Atara Biotherapeutics, Inc. (ATRA) reported a current ratio of 0.82x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Imminent liquidity and solvency risk
Metrics are mathematically derived from official filings.
Rapid Erosion of Asset Base
As reported in recent financial statements, Atara's total assets have plummeted from $165.5 million in 2023Q4 to just $20.0 million by 2026Q1, signaling a severe contraction in the company's resource base as it exhausts capital to fund ongoing clinical development and operational overhead.
The consistent decline in total assets suggests that the company is consuming its remaining capital at an unsustainable rate. This trajectory implies that the firm's ability to support future R&D initiatives is rapidly diminishing, leaving little room for error in its clinical pipeline.
Critical Cash Runway and Solvency
Based on the most recent quarterly filings, Atara's cash and equivalents have dwindled to $8.4 million, a figure that appears dangerously low relative to the company's historical burn rate and suggests an imminent need for external financing to maintain operations as a going concern.
While the current ratio of 2.16 might appear superficially healthy, it is heavily distorted by the low absolute level of current assets and liabilities. Investors should monitor the company's ability to secure non-dilutive funding, as the current liquidity buffer provides minimal protection against operational shocks.
Persistent Negative Equity Position
According to historical balance sheet data, Atara has maintained a persistent negative equity position, which reached -$37.3 million in 2026Q1, reflecting years of accumulated losses that have effectively wiped out shareholder capital and left the company reliant on external capital markets for survival.
The deep hole in retained earnings, which stands at approximately -$2.0 billion, indicates that the company has yet to achieve a self-sustaining business model. This structural deficit suggests that any future value creation for shareholders is contingent upon a successful pivot to commercial-scale revenue.
Deferred Revenue Distorts Liquidity View
As indicated by recent SEC filings, the rapid decline in deferred revenue from $123.9 million in 2024Q1 to $684.0K in 2026Q1 reveals that the company has largely exhausted its previously collected milestone payments, removing a critical non-cash buffer that once supported the balance sheet.
The depletion of this liability is a significant indicator that the company's past financial stability was heavily reliant on upfront payments rather than organic growth. This shift implies that the balance sheet is now fully exposed to the underlying cash burn of the business without the cushion of prior-period receipts.